References
- Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 1995; 118: 707–719.
- Brooks BR, Sanjak M, Belden D, Waclawik A. Motor Neurone Disease: Basic designs, sample sizes and pitfalls. In: Guiloff RJ, ed. Clinical Trials in Neurology. London: Springer-Verlag, 2001: 427–450.
- Steiner TJ. Motor Neurone Disease: Experience with large multi- centre trials. In: Guiloff RJ, ed. Clinical Trials in Neurology. London: Springer-Verlag, 2001: 451–463.
- Heiser V, Engemann S, Brocker W et al. Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington’s disease by using an automated filter retardation assay. Proc Natl Acad Sci USA 2002; 99 (Suppl 4): 16400–16406.
- Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis/riluzole Study Group II. Lancet 1996; 347: 1425–1431.
- Turner MR, Bakker M, Sham P, Shaw CE, Leigh PN, Al-Chalabi A. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2002; 3(1): 15–21.
- Turner MR, Parton MJ, Shaw CE, Leigh PN, Al-Chalabi A. Prolonged survival in motor neuron disease: a descriptive study of the King’s database 1990–2002. J Neurol Neurosurg Psychiatry 2003; 74: 995–997.
- Borasio GD, Robberecht W, Leigh PN et al. A placebo controlled trial of insulin-like growth factor-1 in amyotrophic lateral sclerosis. European ALS/IGF-1 Study Group. Neurology 1998; 51: 583–586.
- Lai EC, Felice KJ, Festoff BW et al. Neurology 1997; 49: 1621–1630.